<DOC>
	<DOCNO>NCT01013974</DOCNO>
	<brief_summary>This single centre , randomize , double blind , placebo control , single repeat dose study investigate safety , tolerability , pharmacokinetics inhale dose GSK573719 lactose contain magnesium stearate novel dry powder device healthy Japanese male subject .</brief_summary>
	<brief_title>A Study GSK573719 Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Japanese healthy male subject age 20 64 year age inclusive . Healthy subject define individual free clinically significant illness disease determine medical history , physical examination , laboratory study , test . 2 . Body weight ≥ 50kg BMI within range 18.525.0kg/m2 inclusive . 3 . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) 4 . Normal spirometry ( FEV1 ≥ 80 % predict , FEV1/FVC ≥ 70 % ) . 5 . Clinical laboratory test data obtain screen meet following : AST ( GOT ) , ALT ( GPT ) , totalbilirubin : upper limit normal range 6 . Normal 12lead EGC find screening ; QTc ( B ) interval &lt; 450msec 7 . A mean blood pressure low 140/90mmHg screening . 8 . Capable give write informed consent , include compliance requirement restriction list consent form . 9 . Capable use novel dry powder inhaler . 1 . The subject clinically relevant abnormality medical examination , vital sign , clinical laboratory test medical history screen medical opinion investigator subject medical history consider eligible inclusion study investigator . 2 . The subject positive syphilis , HBs antigen , HCV antibody , HIV antibody , HTLV1 antibody . 3 . The subject positive urine drug screening . 4 . The subject allergy drug idiosyncrasy 5 . The subject history breathing problem ( i.e . history asthmatic symptomatology ) . 6 . The subject history cardiovascular disease . 7 . The subject significant clinical history current condition glaucoma . 8 . The subject significant clinical history current condition prostatic hypertrophy . 9 . The subject history drug abuse alcoholism . 10 . The subject history cholecystectomy biliary tract disease . 11 . History regular alcohol consumption exceed average , 14 drinks/week ( 1 drink = 5 ounce ( 150 mL ) wine 350 mL beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screening . 12 . Use prescription nonprescription drug , include CYP3A/PGP inhibitor , vitamin , herbal dietary supplement ( include St John'sWort ) within 14 day prior first dose study medication . 13 . The subject currently participate another clinical study postmarketing study subject expose investigational noninvestigational drug device . 14 . The subject participate clinical study investigational noninvestigational drug device previous 4 month . 15 . The subject allergy drug hypersensitivity milk protein excipients lactose monohydrate magnesium stearate . 16 . The subject donate unit blood `` &gt; 400 mL '' within previous 4 month `` &gt; 200 mL '' within previous 1 month .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>